Director/PDMR Shareholding

About this update from Probiotix Health Plc

4 February 2026                                                                                                  ProBiotix Health plc ("ProBiotix Health" or the "Company" or, together with its subsidiary, the "Group")   Director/PDMR Shareholding   ProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to support cardiometabolic health, is pleased to announce that Adam Reynolds, Chairman of the Company, has acquired 150,000 ordinary shares of 0.05p each in the Company ("Ordinary Shares") at a price of 8p per share.   Following this acquisition, Adam Reynolds is interested in Ordinary Shares as follows:   Name Number of Ordinary Shares acquired Resultant Shareholding % Adam Reynolds 150,000 442,857 0.28   Further information about the acquisition of Ordinary Shares is set out in the table below.   For further information, please contact:   ProBiotix Health plc Steen Andersen, Chief Executive Officer Miles Nolan, Investor Relations   https://probiotixhealth-ir.com [email protected]     AlbR Capital Limited Aquis Corporate Adviser and Broker Tel: 020 7469 0930     Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them. 1 Details of the person discharging managerial responsibilities / person closely associated a) Name Adam Reynolds 2 Reason for the notification a) Position/status Chairman b) Initial notification /Amendment   Initial 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer, or auction monitor a) Name ProBiotix Health plc b) LEI 98450048683CF0388C30 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the financial instrument, type of instrument Identification code   ordinary shares of 0.05p each           ISIN: GB00BLNBFR86 b) Nature of the transaction Acquisition of Ordinary Shares c) Price(s) and volume(s) 150,000 shares at 8p per share d) Aggregated information - Aggregated volume - Price     n/a - single transaction e) Date of the transaction 3 February 2026 f) Place of the transaction Aquis Growth Market     This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.  

View stock analysis, news, and events for Probiotix Health Plc